Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.35 USD
Change Today +0.53 / 6.78%
Volume 168.9K
HTBX On Other Exchanges
As of 5:20 PM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

heat biologics inc (HTBX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/9/15 - $10.90
52 Week Low
08/7/14 - $3.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HEAT BIOLOGICS INC (HTBX)

Related News

No related news articles were found.

heat biologics inc (HTBX) Related Businessweek News

No Related Businessweek News Found

heat biologics inc (HTBX) Details

Heat Biologics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. Its Immune Pan-Antigen Cytotoxic Therapy platform technology is designed to educate and stimulate the immune system to combat cancer disease. The company’s products under development include therapeutic vaccine candidates, such as viagenpumatucel-L (HS-110) that is in Phase II clinical trials for the treatment of non-small cell lung cancer; and vesigenurtacel-L (HS-410), which is in Phase II clinical trials for the treatment of non-muscle invasive bladder cancer. It is also developing cell lines for the treatment of ovarian cancer, triple negative breast cancer, and pediatric rhabdomyosarcoma. The company was founded in 2008 and is headquartered in Durham, North Carolina.

14 Employees
Last Reported Date: 03/27/15
Founded in 2008

heat biologics inc (HTBX) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $375.0K
Vice President of Clinical & Regulatory Affai...
Total Annual Compensation: $62.5K
Compensation as of Fiscal Year 2013.

heat biologics inc (HTBX) Key Developments

Heat Biologics, Inc. Announces Unaudited Consolidated Earnings Results for the Year Ended December 31, 2014

Heat Biologics, Inc. announced unaudited consolidated earnings results for the year ended December 31, 2014. For the year, the company announced loss from operations of $12,186,927 compared to $6,564,641 for the same period a year ago. Net loss was $12,243,211 compared to $6,609,864 for the same period a year ago. Net loss attributable to common stockholders was $11,788,817 compared to $9,073,016 for the same period a year ago. Net loss per share attributable to common stockholders, basic and diluted was $1.83 compared to $2.42 for the same period a year ago.

Heat Biologics, Inc. Announces Management Changes

Effective March 15, 2015, Mr. Matthew Czajkowski will resign from his position as Chief Financial Officer of Heat Biologics, Inc., in order to relocate to Kigali, Rwanda to assume the position of Country Director of Jibu, an organization which is working to provide permanent access to safe, affordable water and build locally owned businesses in East Africa. Mr. Czajkowski will also serve as Jibu’s Chief Financial Officer. Mr. Czajkowski’s resignation is not the result of any disagreement with the company. Effective March 15, 2015, Stephen J. DiPalma, age 56, will assume the role of interim Chief Financial Officer of the Company upon the resignation of Mr. Czajkowski. Mr. DiPalma is Managing Director for Danforth Advisors LLC, and brings more than 25 years of experience in life sciences and healthcare, including founding two start-ups, working with venture-backed companies, subsidiaries of Fortune 100 firms and publicly traded companies, and his work as a consultant with Danforth Advisors, LLC clients. Previously, he served as the CFO of two public companies, and as CFO, COO, CEO or Director of eight privately held companies, in addition to his consulting clients.

Heat Biologics Seeks Acquisitions

Heat Biologics, Inc. (NasdaqCM:HTBX) intends to offer for sale shares of its common stock in an underwritten public offering. The company intends to use the net proceeds from this offering for general corporate purposes, which may include, among other things, increasing its working capital, funding research and development (including clinical trials), vendor payables, regulatory submissions, hiring additional personnel and capital expenditures. In addition, the company may use a portion of the net proceeds for licensing or acquiring intellectual property to incorporate into its products and product candidates or its research and development programs or to in-license, acquire or invest in complementary businesses or products.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HTBX:US $8.35 USD +0.53

HTBX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HTBX.
View Industry Companies

Industry Analysis


Industry Average

Valuation HTBX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEAT BIOLOGICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at